

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 July 2025 (17.07.2025)



(10) International Publication Number
WO 2025/151407 A1

(51) International Patent Classification:
A61K 31/7125 (2006.01) *A61K 31/7115* (2006.01)

(21) International Application Number:
PCT/US2025/010552

(22) International Filing Date:
07 January 2025 (07.01.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/618,693 08 January 2024 (08.01.2024) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, California
94080 (US).

(72) Inventors: **DEVOS, Sarah L.**; c/o Denali Therapeutics
Inc., 161 Oyster Point Blvd., South San Francisco, Califor-
nia 94080 (US). **BARKER, Scarlett**; c/o Denali Therapeu-
tics Inc., 161 Oyster Point Blvd., South San Francisco, Cal-
ifornia 94080 (US). **THAYER, Mai B.**; c/o Denali Thera-
peutics Inc., 161 Oyster Point Blvd., South San Francisco,
California 94080 (US). **KLAR, Richard**; c/o Secarna Phar-
maceuticals GmbH & Co. KG, Rudolf-Bultmann-Str. 4H,
35039 Marburg (DE). **MICHEL, Sven**; c/o Secarna Phar-
maceuticals GmbH & Co. KG, Rudolf-Bultmann-Str. 4H,
35039 Marburg (DE). **JASCHINSKI, Frank**; c/o Secarna
Pharmaceuticals GmbH & Co. KG, Rudolf-Bultmann-Str.
4H, 35039 Marburg (DE). **ROTHKIRCH, Larissa**; c/o
Secarna Pharmaceuticals GmbH & Co. KG, Rudolf-Bult-
mann-Str. 4H, 35039 Marburg (DE).

(74) Agent: **EKENA, Kirk** et al.; Alston & Bird LLP, Vantage
South End, 1120 South Tryon Street, Suite 300, Charlotte,
North Carolina 28203-6818 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING ALPHA-SYNUCLEIN EXPRESSION

(57) Abstract: Provided herein are SNCA antisense oligonucleotides that are capable of modulating the expression of a SNCA target nucleic acid. Also provided herein are methods of use thereof.

WO 2025/151407 A1